Welcome to the AAV Germline Transmission Survey!
Current Practices in AAV Gonadal Biodistribution & Germline Transmission Risk Assessment
Note: This survey is specifically directed towards AAV product developers!
Note: This survey is specifically directed towards AAV product developers!
Assessment of vector biodistribution (BD) is a fundamental component of the nonclinical safety package for the development of AAV-based gene therapy products. Regulatory health authorities globally require comprehensive BD data to determine the potential for off-target organ toxicity and long-term risks. One of the critical aspects of this assessment is the evaluation of gonadal tissues. Current regulatory frameworks explicitly expect the use of highly sensitive PCR-based methods to detect vector genomes in the gonads (1, 2, 3).
The 2006 ICH Considerations: General Principles to Address the Risk of Inadvertent Germline Integration of Gene Therapy Vectors remains the most comprehensive foundational document explicitly addressing the risk of germline modification (4). It establishes a critical stepwise approach for determining whether vector signals are present in germ cells (sperm/oocytes) versus non-germline cells (e.g., leukocytes, Sertoli, or Leydig cells) and if germline transmission assessment is warranted. While the guidance acknowledges the distinction between integrating and non-integrating vectors, it was authored nearly two decades ago when the specific data on AAV gonadal transduction and germline transmission was scarce.
Current literature indicates high incidence of positive PCR signals in whole-gonad homogenates for AAV administration, particularly following systemic intravenous administration at high dose levels (5, 6, 7, 8). However, the signal often arises from somatic interstitial cells, and thus far the presence of vector DNA in gonadal tissue does not inherently equate to germline transduction or the risk of vertical transmission to offspring.
In the current regulatory guidance, the framework lacks the benefit of the extensive modern dataset regarding AAV biodistribution and does not provide a standardized flowchart for methodologies to distinguish these signals or define the precise next steps required to contextualize the risk for human patients, leading to uncertainty on how to best apply these principles to the unique, real-world safety profile of AAV today. Due to the lack of a unified harmonized approach, developers employ a wide variety of ancillary assays—ranging from basic In Situ Hybridization (ISH) to complex breeding studies—with varying degrees of value and regulatory acceptance.
The objective of this survey is to aggregate anonymous data from AAV product developers across academia, biotechnology, and the pharmaceutical industry to better understand the real-world landscape of AAV germline risk assessment. Specifically, this survey aims to:
- Quantify Incidence: Assess the frequency of gonadal transduction via standard PCR across different AAV serotypes and routes of administration.
- Map Industry Practices: Identify which follow-up methods (e.g., IHC, ISH, single-cell sequencing, integration analysis) are currently being used to distinguish transduction of somatic vs. germline signals.
- Evaluate Breeding Studies: Determine the frequency, design, and outcomes of functional germline transmission (breeding) studies.
- Assess Regulatory Feedback: Gather insights into what regulatory authorities are currently requesting and which scientific approaches they accept as sufficient evidence of safety.
- Determine Value: Critically evaluate whether these extensive nonclinical datasets are truly aiding in human risk assessment or simply serving as a "box-checking" exercise.
- Promote Global Harmonization: Provide a data-driven basis to advocate for consistent, scientifically justified expectations from global health authorities (FDA, EMA, PMDA, etc.), thereby reducing regulatory divergence and helping streamline AAV product development.
If your company or institution has multiple programs, please submit a separate response for each!
Confidentiality: All responses are strictly confidential and will be aggregated to ensure no specific company or program can be identified. Your participation will help establish a benchmark for the industry and potentially inform future regulatory interactions regarding the necessity and design of these studies. Your name and contact information is requested only in the event we need to follow up with any clarifying questions.
To help you prepare your responses, you may review the survey questions in advance by downloading a Word version here. Final responses should be submitted through the web survey.
To help you prepare your responses, you may review the survey questions in advance by downloading a Word version here. Final responses should be submitted through the web survey.